24/7 Market News Memorial Day Weekend weekly Wrap-up

SciSparc Ltd. (NASDAQ:SPRC) announced that its collaboration with Clearmind Medicine Inc. yielded  positive safety profile results from its joint pre-clinical trial, which tested the proprietary combination of SciSparc’s CannAmide(TM) with Clearmind’s psychedelic molecule, MEAI, for alcohol consumption. Shares almost doubled at the open on Tuesday, as it nearly hit $4, and yielded wild price swings since, but this morning SciSparc announced that it will issue 3,546,100 units and pre-funded units at a purchase price of $2.82 per unit (or $0.001 less per pre-funded unit), in an at-the-market priced transaction.

Concert Pharmaceuticals Inc (NASDAQ:CNCE), a clinical stage biopharmaceutical company that’s developing small molecule drugs, has made several wave moves since we first covered it, hitting a new 52 week high today of $6.80 and closing today at $5.88, 86 cents higher (+17.13%), on 5,410,143 shares.

The Lexington, Massachusetts based pharmaceutical company recently reported positive topline results for First CTP-543 Phase 3 clinical trial in Alopecia Areata and the highlights included; THRIVE-AA1 Study Meets Primary Endpoint for Scalp Hair Regrowth and Key Secondary Endpoints at Both Doses, Statistically Significant Hair Regrowth Observed as Early as Eight Weeks, CTP-543 Has Potential to be Best-in-Class for the Treatment of Alopecia Areata, and Topline Data from Second Phase 3 Trial, THRIVE-AA2, Expected Third Quarter of 2022

Even though the close is 92 cents off of its high, Concert Pharmaceuticals may still be in play, as a consolidation near this level would be a very healthy response to its recent monster moves, so don’t be surprised if we call this one again.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.